Breaking up long sitting periods to improve heart health and reduce chemo side effects in adults with lymphoma on R-CHOP or POLA-R-CHP

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized pilot trial will assign about 24 newly diagnosed adult lymphoma patients receiving first-line R-CHOP or POLA-R-CHP to either a 12-week interrupted sedentary time intervention or usual care. The intervention encourages regular short activity breaks to reduce prolonged sitting and includes supervised and unsupervised components plus text-message support. Study measures include feasibility outcomes, cardiometabolic blood markers, fitness assessments, and patient-reported chemotherapy toxicity collected at baseline and after 12 weeks. All study visits and exercise sessions occur at Dana-Farber Cancer Institute in Boston.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Ability to understand and the willingness to sign informed consent prior to any study- related procedures.
* Patients diagnosed with lymphoma.
* Will receive first line R-CHOP or POLA-R-CHP chemotherapy regimens, patients do not need to be within a certain timeframe from diagnosis.
* Aged ≥18 years; due to the rarity of the disease in those \<18 years, this age bracket will not be included.
* Engaging in ≤60-minutes of structured moderate or vigorous intensity exercise.
* Have physician clearance to participate in exercise.
* Speak English.
* Willing to travel to Dana-Farber Cancer Institute for necessary data collection and exercise sessions.
* Access to a phone that can receive text messages.

Exclusion Criteria:

* Unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Patients with unstable comorbidities likely require supervised exercise for safety, and part of this study involves unsupervised exercise; therefore, for safety reasons, these persons are excluded.
* Participate in more than 60 minutes of structured moderate-to-vigorous exercise per week over the last month. Excess additional exercise is a confounding factor in assessing the effect of the current interrupted sedentary time intervention.
* Patients receiving treatment for other active malignancies (except basal cell carcinoma). This study is exclusively targeting lymphoma chemotherapy-related effects.
* Patients currently taking weight loss drugs.
* Subjects who in the opinion of the investigators may not be able to comply with the safety monitoring requirements of the study.
* Unable to travel to DFCI Longwood campus for necessary data collection and chemotherapy infusions.

Where it's running

• Dana Farber Cancer Institute
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Christina Dieli-Conwright, MD, PhD — Dana-Farber Cancer Institute
• Study coordinator: Christina Dieli-Conwright, MD, PhD
• Email: ChristinaM_Dieli-Conwright@dfci.harvard.edu
• Phone: 617-582-8321

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TLN-121 for relapsed or refractory non-Hodgkin lymphoma

  We will test TLN-121 by itself and together with other lymphoma treatments in people whose non-Hodgkin lymphoma has returned or did not respond to prior therapies.

  Recruiting at 14 sites Phase 1 Treeline Biosciences, Inc. · Palo Alto, California and 13 other locations · NCT07082803

• T-Cell Therapy for Adults with Relapsed B-Cell Non-Hodgkin's Lymphoma

  This study is testing a new T-cell therapy to see if it can help adults with relapsed B-cell non-Hodgkin's lymphoma feel better.

  Recruiting at 5 sites Phase 1/2 Estrella Immunopharma, Inc. · Sacramento, California and 4 other locations · NCT06343311

• Depleting specific immune cells in stem cell transplants for blood cancers

  This study is testing if removing certain immune cells during stem cell transplants can help children and young adults with blood cancers have better outcomes and fewer complications.

  Recruiting Phase 2 University of Florida · Gainesville, Florida · NCT05800210

• Cohort study for patients with aggressive lymphoma

  This study looks at patients with aggressive lymphoma to see how well standard treatments work and how the disease changes over time.

  Recruiting Samsung Medical Center · Seoul · NCT03117036

• LB-208: a new oral treatment for adults with advanced solid tumors or lymphoma

  This early study tests whether LB-208, taken once daily by mouth, is safe for adults with advanced solid tumors or lymphoma who have exhausted standard treatments.

  Recruiting Phase 1 Leukos Biotech S.L. · Barcelona, Barcelona · NCT07914348

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.